Literature DB >> 29089606

The inflammatory microenvironment and microbiome in prostate cancer development.

Karen S Sfanos1,2,3, Srinivasan Yegnasubramanian1,2, William G Nelson1,2,3, Angelo M De Marzo1,2,3.   

Abstract

Chronic inflammation promotes the development of several types of solid cancers and might contribute to prostate carcinogenesis. This hypothesis partly originates in the frequent observation of inflammatory cells in the prostate microenvironment of adult men. Inflammation is associated with putative prostate cancer precursor lesions, termed proliferative inflammatory atrophy. Inflammation might drive prostate carcinogenesis via oxidative stress and generation of reactive oxygen species that induce mutagenesis. Additionally, inflammatory stress might cause epigenetic alterations that promote neoplastic transformation. Proliferative inflammatory atrophy is enriched for proliferative luminal epithelial cells of intermediate phenotype that might be prone to genomic alterations leading to prostatic intraepithelial neoplasia and prostate cancer. Studies in animals suggest that inflammatory changes in the prostate microenvironment contribute to reprogramming of prostate epithelial cells, a possible step in tumour initiation. Prostatic infection, concurrent with epithelial barrier disruption, might be a key driver of an inflammatory microenvironment; the discovery of a urinary microbiome indicates a potential source of frequent exposure of the prostate to a diverse number of microorganisms. Hence, current evidence suggests that inflammation and atrophy are involved in prostate carcinogenesis and suggests a role for the microbiome in establishing an inflammatory prostate microenvironment that might promote prostate cancer development and progression.

Entities:  

Mesh:

Year:  2017        PMID: 29089606     DOI: 10.1038/nrurol.2017.167

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  142 in total

Review 1.  Intestinal epithelial cells: regulators of barrier function and immune homeostasis.

Authors:  Lance W Peterson; David Artis
Journal:  Nat Rev Immunol       Date:  2014-03       Impact factor: 53.106

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 3.  Thirty years of research on infection and prostate cancer: no conclusive evidence for a link. A systematic review.

Authors:  Jan Hrbacek; Michael Urban; Eva Hamsikova; Ruth Tachezy; Jiri Heracek
Journal:  Urol Oncol       Date:  2012-03-28       Impact factor: 3.498

Review 4.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

5.  Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis.

Authors:  J Curtis Nickel; Jim Xiang
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

6.  Prostatic antibacterial factor. Identity and significance.

Authors:  W R Fair; J Couch; N Wehner
Journal:  Urology       Date:  1976-02       Impact factor: 2.649

7.  A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms.

Authors:  Karen S Sfanos; Jurga Sauvageot; Helen L Fedor; James D Dick; Angelo M De Marzo; William B Isaacs
Journal:  Prostate       Date:  2008-02-15       Impact factor: 4.104

8.  CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.

Authors:  Sabina Davidsson; Anna-Lena Ohlson; Swen-Olof Andersson; Katja Fall; Allison Meisner; Michelangelo Fiorentino; Ove Andrén; Jennifer R Rider
Journal:  Mod Pathol       Date:  2012-10-05       Impact factor: 7.842

9.  Prostatitis as a risk factor for prostate cancer.

Authors:  Rosebud O Roberts; Erik J Bergstralh; Sarah E Bass; Michael M Lieber; Steven J Jacobsen
Journal:  Epidemiology       Date:  2004-01       Impact factor: 4.822

10.  Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing.

Authors:  Young-Do Nam; Hak Jae Kim; Jae-Gu Seo; Seung Wan Kang; Jin-Woo Bae
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  99 in total

Review 1.  Human microbiome and prostate cancer development: current insights into the prevention and treatment.

Authors:  Solmaz Ohadian Moghadam; Seyed Ali Momeni
Journal:  Front Med       Date:  2020-06-30       Impact factor: 4.592

2.  Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls.

Authors:  K S Smith; A D Frugé; W van der Pol; N E Caston; C D Morrow; W Demark-Wahnefried; T L Carson
Journal:  Benef Microbes       Date:  2021-04-01       Impact factor: 4.205

Review 3.  The microbiome and gynaecological cancer development, prevention and therapy.

Authors:  Paweł Łaniewski; Zehra Esra Ilhan; Melissa M Herbst-Kralovetz
Journal:  Nat Rev Urol       Date:  2020-02-18       Impact factor: 14.432

Review 4.  [The role of the microbiome in urology].

Authors:  G Magistro; J Marcon; L Eismann; Y Volz; C G Stief
Journal:  Urologe A       Date:  2020-12       Impact factor: 0.639

5.  Longitudinal Assessment of Prevalence and Risk Factors of Anxiety and Depression among Prostate Cancer Survivors Post-Resection.

Authors:  Ruibin Yu; Haibo Li
Journal:  Psychiatr Q       Date:  2021-01-06

6.  Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Giovanni Novella; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Aliasger Shakir; Arianna Mariotto; Matteo Brunelli; Maria Angela Cerruto; Giovanni Enrico Cacciamani; Filippo Migliorini; Salvatore Siracusano; Walter Artibani
Journal:  World J Urol       Date:  2019-06-01       Impact factor: 4.226

7.  The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.

Authors:  Andreas M Hötker; Evelyn Dappa; Yousef Mazaheri; Behfar Ehdaie; Junting Zheng; Marinela Capanu; Hedvig Hricak; Oguz Akin
Journal:  AJR Am J Roentgenol       Date:  2019-02-04       Impact factor: 3.959

8.  Synchronous genitourinary lichen sclerosus signals a distinct urinary microbiome profile in men with urethral stricture disease.

Authors:  Andrew J Cohen; Thomas W Gaither; Sudarshan Srirangapatanam; Erick R Castellanos; Anthony Enriquez; Kirkpatrick B Fergus; Douglas Fadrosh; Susan Lynch; Nnenaya A Mmonu; Benjamin N Breyer
Journal:  World J Urol       Date:  2020-04-09       Impact factor: 4.226

Review 9.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

10.  Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study.

Authors:  Travis J Meyers; Adam B Weiner; Rebecca E Graff; Anuj S Desai; Lauren Folgosa Cooley; William J Catalona; Stephen B Hanauer; Jennifer D Wu; Edward M Schaeffer; Sarki A Abdulkadir; Shilajit D Kundu; John S Witte
Journal:  Int J Cancer       Date:  2020-05-29       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.